European Union’s drug regulator said it has found a possible blood clot link with the Johnson & Johnson vaccine but stressed the benefits of the shot outweigh the risk, coming about a week after U.S. health regulators recommended a pause. The European Medicines Agency (EMA) said its “safety committee concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen,” according to a statement published Tuesday. “Healthcare professionals and people who will receive the vaccine should be aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within three weeks of vaccination,” the statement added. The agency said it researched at least eight reports, including a death, from the United States about cases involving unusual blood clots occurring after the COVID-19 vaccine was administered. It noted that more than …